Christopher Huhta, MD
Pulmonary Disease · Lansing, MINPI 1104859032
Payments from drug & device makers
Across 346 payments — averaging $36.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Grifols USA, LLC$594
- GSK$568
- Sanofi$436
- plus $2K from 24 others
What the payments were for
- Consulting fees$4003%
- Travel & lodging$2,04816%
- Food & beverage$6,12148%
- Education$4,09532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $6,048 |
| AstraZeneca(2 entities) | 92 | $1,820 |
| Boehringer Ingelheim | 55 | $1,039 |
| Grifols USA, LLC | 32 | $594 |
| GSK | 37 | $568 |
| Sanofi | 21 | $436 |
| Actelion Pharmaceuticals US, Inc. | 17 | $424 |
| Bayer | 3 | $422 |
| Regeneron Healthcare Solutions, Inc. | 22 | $306 |
| Mylan Specialty L.p. | 12 | $238 |
| Amgen | 5 | $86 |
| Merck | 4 | $73 |
| Insmed, Inc. | 4 | $72 |
| Sunovion Pharmaceuticals Inc. | 6 | $63 |
| Philips North America LLC | 4 | $62 |
| Viatris Specialty LLC | 3 | $59 |
| Verona Pharma, Inc. | 2 | $43 |
| Genentech USA, Inc. | 3 | $43 |
| 3b Medical, Inc. | 1 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| United Therapeutics Corporation | 1 | $22 |
| Resmed Corp | 1 | $21 |
| Pfizer | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Covidien LP | 1 | $13 |
| Electromed, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,664 in reported general payments places this provider in the 75th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $344,375 |
| OfevNintedanib Esylate | 22 | $293,582 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 253 | $210,891 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 107 | $73,741 |
| Dupixent PenDupilumab | 11 | $43,090 |
| SymbicortBudesonide/Formoterol Fumarate | 109 | $31,332 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 68 | $26,839 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 33 | $20,798 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $17,759 |
| Spiriva RespimatTiotropium Bromide | 28 | $16,986 |
| Advair HfaFluticasone Propion/Salmeterol | 34 | $14,223 |
| DuleraMometasone/Formoterol | 38 | $13,644 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $4,502 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $4,028 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $3,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $594 | $344,37523 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,039 | $331,36583 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $568 | $228,650290 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,820 | $105,073216 claims |
| MerckDulera | $73 | $13,64438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Lansing
- Jennifer ElyLansing$37K
- David YoungLansing$36K
- Njira LugogoAnn Arbor$12.9M
- Timothy BlackwellAnn Arbor$2.5M
- Kevin FlahertyAnn Arbor$2.3M
- Meilan HanAnn Arbor$1.8M
- Gary FergusonLivonia$1.5M
- Justin OldhamAnn Arbor$1.4M
- Robert PaineAnn Arbor$1.3M
- Irina ShanidzeFarmington Hills$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.